Bio-rad Laboratories Stock News

Bio-Rad Laboratories (NYSE: BIO.B) is one of 42 public companies in the Analytical instruments industry, but how does it weigh in compared to its peers? We will compare Bio-Rad Laboratories to similar companies based on the strength of its dividends, institutional ownership, profitability, analyst recommendations, earnings, valuation and risk. Earnings & Valuation This table compares []

Fundamentun LLC acquired a new stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 332 shares of the medical research companys stock, valued at approximately $248,000. Other hedge funds have also recently bought and sold shares []

"Lateral Flow Assay Market, Drug Price, Sales and Clinical Trials Insight 2028 Report Highlights: Lateral Flow Assay Market Opportunity: > US$ 10.1 Billion by 2028 Lateral Flow Assay Market Growth: 100% Absolute Growth Till 2028 Lateral Flow Assay Market Size Opportunity by

Blood Bank Information System This Blood Bank Information System (BBIS) is connecting hospitals, UTD PMI, and personal donors within one web-based and mobile application. Web service, database service, and transaction-based service are the ideal applications for cloud computing. Ensures hospitals

Bio-Rad Laboratories, Inc. (NYSE:BIO.B)s share price hit a new 52-week high during mid-day trading on Monday . The company traded as high as $750.16 and last traded at $750.16, with a volume of 213 shares changing hands. The stock had previously closed at $769.89. The firm has a market cap of $22.44 billion, a price-to-earnings []

Global Prepacked Chromatography Columns market Overview Single-use innovations make manufacturing simpler with prepackaged chromatography columns. Equipment capital and qualification, asset traceability, calibration, and routine maintenance are all eliminated with these columns. Prepackaged chromatography columns often save money on materials and consumables associated

DUBLIN--(BUSINESS WIRE)--The "Endocrine Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com''s offering. The global endocrine testing market reached a value of US$ 10 Billion in 2020. Looking forward, the publisher expects the market to grow at a CAGR of 8.7% during 2021-2026. Companies Mentioned Abbott Laboratories Agilent Technologies Inc. Bio-Rad Laboratories Inc. BioMerieux SA DiaSorin S.p.A. F. Hoff

The global Cell Analysis Technology market size is projected to a CAGR of 14.2% during 2021-2027. Worldwide Cell Analysis Technology Market 2021-2027 industry report examines the development openings just as the dangers to the Cell Analysis Technology Market w.r.t Business

Atticus Wealth Management LLC lifted its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 68.3% in the 3rd quarter, Holdings Channel reports. The firm owned 234 shares of the medical research company’s stock after acquiring an additional 95 shares during the period. Atticus Wealth Management LLC’s holdings in Bio-Rad Laboratories were worth $175,000 at […]

Enzyme-linked immunosorbent assay (ELISA) is a labeled immunoassay that is considered the gold standard of immunoassays. This immunological test is very sensitive and is used to detect and quantify substances, including antibodies, antigens, proteins, glycoproteins, and hormones. The enzyme-linked immunosorbent assay

This IPO didn''t go to plan The post The Biome Australia (ASX: BIO) share price just flopped on IPO appeared first on The Motley Fool Australia .

According to the new market research report Therapeutic Drug Monitoring Market by Product (Equipment (Immunoassay Analyzers), Consumables), Technology (Immunoassays, Chromatography-MS), Class of Drugs (Antibiotic Drugs, Bronchodilator Drugs), End User Global Forecast to 2025, published by MarketsandMarkets, the TDM Market is projected to reach USD 2.0 billion by 2025 from USD 1.4 billion in 2020, at []

Bio-Rad Laboratories (NYSE: BIO.B) is one of 42 public companies in the Analytical instruments industry, but how does it contrast to its competitors? We will compare Bio-Rad Laboratories to related companies based on the strength of its analyst recommendations, institutional ownership, risk, profitability, earnings, dividends and valuation. Profitability This table compares Bio-Rad Laboratories and its []

Bio-Rad Laboratories (NYSE: BIO.B) is one of 42 public companies in the Analytical instruments industry, but how does it contrast to its competitors? We will compare Bio-Rad Laboratories to related businesses based on the strength of its dividends, risk, analyst recommendations, valuation, earnings, profitability and institutional ownership. Earnings & Valuation This table compares Bio-Rad Laboratories []

Biosensors Market to Reach US$ 43,073.2 Million By 2027 Biosensors comprises of the biological recognition unit, having the ability of interacting with bioelements, including living tissue, antibodies, enzymes, as well as a transducer that is used for changing the bioelement